ClinicalTrials.gg
CompletedNCT01534182EPOCUpdated Aug 8, 2014Results posted

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

A Phase 4 interventional study of Fingolimod and Interferon beta - 1a (IFN) in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
7th of 19
298 · median 142
Started
2012
with 3 others
Phase 4
14 of 19
none open now
Registered
9th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 7th largest by enrollment, is one of 4 that started in 2012, is one of 14 in phase 4, and was the 9th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (fingolimod) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis

Keywords

  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Fingolimod
  • Disease Modifying Therapy (DMT)
  • TSQM-9
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Patients must be diagnosed with relapsing remitting MS (RRMS) as defined by 2005 revised McDonald criteria (McDonald et al 2001, Polman et al 2005) (Appendix 2).
  • Patients who explicitly agree to be assigned to a treatment group that may receive or DMT after having been informed about their respective benefits and possible adverse events by the investigator.
  • Male or female patients aged 18-70 years.
  • An Expanded Disability Status Scale (EDSS) score of 0-6 inclusive.
  • Must have received continuous treatment with a single approved and indicated MS DMT for a minimum of 6 months prior to the screening visit. Patients must continue with this MS DMT until the randomization visit.
  • Naïve to treatment with fingolimod.

Exclusion criteria

Exclusion Criteria:

  • A manifestation of MS other than those defined in the inclusion criteria.
  • A history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.
  • History of of any organ system.
  • Diagnosis of macular edema during Screening Phase.
  • Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to have positive antibody test.
  • Patients who have received any live or (including for varicella-zoster virus or measles) within 2 months prior to baseline.
  • Patients who have received total lymphoid irradiation or bone marrow transplantation.
  • History of selected immune system treatments and/or medications.
  • Any medically unstable condition, as assessed by the investigator.
  • Selected cardiovascular, or hepatic conditions
  • Selected abnormal laboratory values.
  • Patients with any other disease or clinical condition (including neurologic or psychiatric disorders) which may affect patient enrollment into the study and study medication use by the Investigators' opinion.
  • Participation in any clinical research study evaluating another not approved in Russia drug or therapy within 6 months prior to baseline.
  • History of to the study drug or to drugs of similar chemical classes.
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
298 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Participants received 0.5 mg orally once a day.

    Drug: Fingolimod

  • Active comparator
    Standard Disease Modifying Therapy (DMT)

    Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.

    Drug: Interferon beta - 1a (IFN) · Drug: Glatiramer acetate (GA)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Patient-reported Treatment Satisfaction

    The Treatment Satisfaction Questionnaire for Medication (TSQM) contains 14 items assessing the following 4 domains: effectiveness (items 1 - 3), side effects (items 4 - 8), convenience (items 9 - 11) and global satisfaction (items 12 - 14). The primary outcome was measured on the global satisfaction domain. Item 12 scored as 1 (not at all confident) to 5 (extremely confident); item 13 scored as 1 (not at all certain) to 5 (extremely certain); and item 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). Responses to items were summed and transformed: specifically, TSQM v 1.4 domain scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death

    Participants were monitored for adverse events, serious adverse events and death throughout the study.

    Time frame: 6 months

  2. Changes in Patient-reported Effectiveness, Side Effects and Convenience

    TSQM v 1.4 domains for effectiveness, side effects and convenience were used to evaluate this outcome. The effectiveness domain for items 1 - 3 was scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the side effects domain, item 4 scored as 0(no) or 1(yes); item 5 scored as 1 (extremely bothersome) to 5 (not at all bothersome); and items 6 - 8 scored as 1 (a great deal) to 5 (not at all). For the convenience domain, items 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and item 11 scored as 1 (extremely inconvenient) to 7 (extremely convenient). For each domain, scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.

    Time frame: Baseline, 6 months

  3. Change in Patient-reported Depression

    The Beck Depression Inventory (BDI-I) scale was used to measure this outcome. The scale consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each item was scored from 0 - 3. If more than one score was provided for an item, the maximum score was considered the item score. The total score was calculated as the sum of all individual items and then compared to a key to determine the depression's severity. The standard key ranges were: 0 - 9 indicated minimal depression; 10 - 18 indicated mild depression; 19 - 29 indicated moderate depression and 30 - 63 indicated severe depression. Higher total scores indicate more severe depressive symptoms.

    Time frame: Baseline, 6 months

  4. Change in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Acute (SF-36 v2 Acute)

    The SF-36 is a health-related quality of life instrument used in numerous disease states, including MS (Brazier et al 1992). It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each domain was scored by adding the individual items from the domain and transforming the resulting scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

    Time frame: Baseline, 6 months

07

Results

Posted Aug 8, 2014

Participant flow

Participants at screening received standard DMT with either interferon beta-1a or glatiramer acetate from day -30 to day -1.

Participant flow — Overall Study
MilestoneFingolimodStandard Disease Modifying Therapy (DMT)
Started23068
Safety set23064
Full analysis set22962
Completed21858
Not completed1210
Withdrew: Administrative problems10
Withdrew: Withdrawal by subject47
Withdrew: Adverse event73

Outcome measures

PrimaryChange in Patient-reported Treatment Satisfaction

The Treatment Satisfaction Questionnaire for Medication (TSQM) contains 14 items assessing the following 4 domains: effectiveness (items 1 - 3), side effects (items 4 - 8), convenience (items 9 - 11) and global satisfaction (items 12 - 14). The primary outcome was measured on the global satisfaction domain. Item 12 scored as 1 (not at all confident) to 5 (extremely confident); item 13 scored as 1 (not at all certain) to 5 (extremely certain); and item 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). Responses to items were summed and transformed: specifically, TSQM v 1.4 domain scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.

Time frame:
Baseline, 6 months
Reported as:
Mean · scores on a scale
Change in Patient-reported Treatment Satisfaction
scores on a scaleFingolimodStandard Disease Modifying Therapy (DMT)
Change in Patient-reported Treatment Satisfaction22.69 ± 28.1213.92 ± 30.63
SecondaryNumber of Patients Who Experienced Adverse Events, Serious Adverse Events and Death

Participants were monitored for adverse events, serious adverse events and death throughout the study.

Time frame:
6 months
Reported as:
Number · Participants
Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death
ParticipantsFingolimodStandard Disease Modifying Therapy (DMT)
Adverse events (serious and non-serious)7326
Serious adverse events20
Deaths00
SecondaryChanges in Patient-reported Effectiveness, Side Effects and Convenience

TSQM v 1.4 domains for effectiveness, side effects and convenience were used to evaluate this outcome. The effectiveness domain for items 1 - 3 was scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the side effects domain, item 4 scored as 0(no) or 1(yes); item 5 scored as 1 (extremely bothersome) to 5 (not at all bothersome); and items 6 - 8 scored as 1 (a great deal) to 5 (not at all). For the convenience domain, items 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and item 11 scored as 1 (extremely inconvenient) to 7 (extremely convenient). For each domain, scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.

Time frame:
Baseline, 6 months
Reported as:
Mean · scores on a scale
Changes in Patient-reported Effectiveness, Side Effects and Convenience
scores on a scaleFingolimodStandard Disease Modifying Therapy (DMT)
Effectiveness21.57 ± 24.0111.56 ± 20.70
Side effects26.75 ± 35.8313.07 ± 40.19
Convenience25.38 ± 20.7210.57 ± 20.93
SecondaryChange in Patient-reported Depression

The Beck Depression Inventory (BDI-I) scale was used to measure this outcome. The scale consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each item was scored from 0 - 3. If more than one score was provided for an item, the maximum score was considered the item score. The total score was calculated as the sum of all individual items and then compared to a key to determine the depression's severity. The standard key ranges were: 0 - 9 indicated minimal depression; 10 - 18 indicated mild depression; 19 - 29 indicated moderate depression and 30 - 63 indicated severe depression. Higher total scores indicate more severe depressive symptoms.

Time frame:
Baseline, 6 months
Reported as:
Mean · scores on a scale
Change in Patient-reported Depression
scores on a scaleFingolimodStandard Disease Modifying Therapy (DMT)
Change in Patient-reported Depression-2.88 ± 6.80-1.86 ± 8.04
SecondaryChange in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Acute (SF-36 v2 Acute)

The SF-36 is a health-related quality of life instrument used in numerous disease states, including MS (Brazier et al 1992). It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each domain was scored by adding the individual items from the domain and transforming the resulting scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

Time frame:
Baseline, 6 months
Reported as:
Mean · scores on scale
Change in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Acute (SF-36 v2 Acute)
scores on scaleFingolimodStandard Disease Modifying Therapy (DMT)
Physical functioning (n=225,61)3.62 ± 16.231.39 ± 14.23
Role limitations due to physical health (n=226,61)6.50 ± 21.994.30 ± 27.52
Bodily pain (n=225,61)5.24 ± 23.790.93 ± 22.95
General health (n=226,61)4.28 ± 17.724.43 ± 22.57
Vitality (n=226,61)7.72 ± 18.611.95 ± 21.97
Social functioning (n=226,61)5.59 ± 23.361.64 ± 23.77
Role limit. due to emotional problems (n=224,61)7.18 ± 25.985.33 ± 27.00
Mental health (n=226,61)5.60 ± 18.552.79 ± 22.09
Physical component summary (n=222,61)1.51 ± 5.690.68 ± 6.57
Mental component summary (n=222,61)3.16 ± 9.661.68 ± 11.31

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod—2/230 (0.9%)39/230 (17%)
Standard Disease Modifying Therapy (DMT): Interferon Beta-1a—0/28 (0%)13/28 (46.4%)
Standard Disease Modifying Therapy: Glatiramer Acetate—0/36 (0%)10/36 (27.8%)
Most frequent serious events
Most frequent serious events
EventFingolimodStandard Disease Modifying Therapy (DMT): Interferon Beta-1aStandard Disease Modifying Therapy: Glatiramer Acetate
Foot FractureInjury, poisoning and procedural complications1/2300/280/36
Renal colicRenal and urinary disorders1/2300/280/36
Most frequent other events
Most frequent other events
EventFingolimodStandard Disease Modifying Therapy (DMT): Interferon Beta-1aStandard Disease Modifying Therapy: Glatiramer Acetate
Influenza like illnessGeneral disorders0/23010/280/36
Injection site painGeneral disorders0/2301/286/36
LymphopeniaBlood and lymphatic system disorders27/2300/282/36
Injection site erythemaGeneral disorders0/2300/283/36
Alanine aminotransferase increasedInvestigations11/2302/280/36
Gamma-Glutamyltransferase increasedInvestigations13/2301/280/36
Injection site extravasationGeneral disorders0/2300/282/36

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FingolimodStandard Disease Modifying Therapy (DMT)Total
Mean35.4 ± 9.936.4 ± 9.335.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)FingolimodStandard Disease Modifying Therapy (DMT)Total
Female16250212
Male681886
08

Study locations

26 sites
  • Novartis Investigative Site
    Arkhangelsk, Russia 163045, Russian Federation
  • Novartis Investigative Site
    Barnaul, 656024, Russian Federation
  • Novartis Investigative Site
    Belgorod, 308007, Russian Federation
  • Novartis Investigative Site
    Kazan, 420021, Russian Federation
  • Novartis Investigative Site
    Kemerovo, 650066, Russian Federation
  • Novartis Investigative Site
    Khanty-Mansiysk, 628012, Russian Federation
  • Novartis Investigative Site
    Kirov, 610014, Russian Federation
  • Novartis Investigative Site
    Krasnodar, 350086, Russian Federation
  • Novartis Investigative Site
    Kursk, 305007, Russian Federation
  • Novartis Investigative Site
    Moscow, 119992, Russian Federation
  • Novartis Investigative Site
    Moscow, 127018, Russian Federation
  • Novartis Investigative Site
    N.Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Nizhniy Novgorod, 603076, Russian Federation
  • Novartis Investigative Site
    Nizhny Novgorod, 603155, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630087, Russian Federation
  • Novartis Investigative Site
    Perm, 614990, Russian Federation
  • Novartis Investigative Site
    Saransk, 430032, Russian Federation
  • Novartis Investigative Site
    Saratov, 410030, Russian Federation
  • Novartis Investigative Site
    Smolensk, 214019, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197376, Russian Federation
  • Novartis Investigative Site
    Tomsk, 634050, Russian Federation
  • Novartis Investigative Site
    Tumen, 625048, Russian Federation
  • Novartis Investigative Site
    Tver, 170036, Russian Federation
  • Novartis Investigative Site
    Ufa, 450000, Russian Federation
  • Novartis Investigative Site
    Ulyanovsk, 432063, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150030, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2012
First posted
Feb 16, 2012
Start
Jan 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 8, 2014
Last update
Aug 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01534182
Responsible party
Sponsor
First posted
Feb 16, 2012
Start date
Jan 2012
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 8, 2014
Last update
Aug 8, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion